Core Viewpoint - The overall sales expense ratio of Kelun Pharmaceutical has decreased due to refined management of the sales system and cost reductions from centralized procurement [1] Group 1 - The sales expense ratio experienced a slight increase in the second quarter compared to the first quarter, primarily due to high promotional costs associated with the launch of Botai's innovative drug products [1] - Excluding the impact of the new product launch, the overall sales expense ratio remains relatively stable [1]